Recruiting Clinical Trials

Displaying 11 - 20 of 245 result(s)
Study Title Condition Phase Location
A 52 Week Randomized, Single-masked, Multicenter Proof of Concept Study of Binocular Videogames Versus Patching for Amblyopia in Children 4-7 Years of Age With an Open-label Substudy of Binocular Videogames in Children 8-12 Years of Age Amblyopia Phase 1
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Canada
An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive Phase 4
  • Country: 
    France
  • Country: 
    Korea, Republic of
  • Country: 
    Singapore
  • Country: 
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients IgA Nephropathy Phase 3
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Australia
  • Country: 
A 52 Week, Multi-center, Randomized, Double-blind Placebo-controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (QGE031) in Decreasing the Sensitivity to Peanuts in Patients With Peanut Allergy Allergy, Peanut Phase 3
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Canada
  • Country: 
A Multi-center, Open-label Study to Determine the Dose and Safety of Oral Asciminib in Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP), Previously Treated With One or More Tyrosine Kinas ... Myeloid Leukemia, Philadelphia Positive Phase 1, Phase 2
  • Country: 
    United States
  • Country: 
    France
  • Country: 
    Germany
  • Country: 
An Open Label, Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Completed PNH Phase 2 and Phase3 Studies With ... Paroxysmal Nocturnal Hemoglobinuria Phase 3
  • Country: 
    Brazil
  • Country: 
    Czech Republic
  • Country: 
    France
  • Country: 
A Phase Ib, Multi-center, Open-label Dose Escalation and Expansion Platform Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma (NHL) Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma Phase 1
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    China
  • Country: 
A Prospective, 16 Week, Phase IV Study to Evaluate Safety, Tolerability and Effectiveness in Patients With Severe Dementia of the Alzheimer's Type Exposed to Rivastigmine (Exelon)15cm2 Transdermal Patch Alzheimer's Disease Phase 4
  • Country: 
    India
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive Phase 3
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Austria
  • Country: 
A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas Metastatic Uveal Melanoma Phase 1, Phase 2
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Switzerland